Ligand Pharmaceuticals 

$263.14
46
+$7.89+3.09% Today

Statistics

Day High
267.27
Day Low
255
52W High
267.27
52W Low
110
Volume
347,697
Avg. Volume
219,617
Mkt Cap
5.25B
P/E Ratio
33.27
Dividend Yield
-
Dividend
-

Upcoming

Dividends

0%Dividend Yield
Jul 10
$0.46
Apr 7
$15.00
10Y Growth
N/A
5Y Growth
N/A
3Y Growth
N/A
1Y Growth
N/A

Earnings

11AugExpected
Q3 2024
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Next
1.19
1.82
2.46
3.09
Expected EPS
1.99
Actual EPS
N/A

Financials

46.42%Profit Margin
Profitable
2020
2021
2022
2023
2024
2025
536.17MRevenue
248.91MNet Income

Analyst Ratings

270.80Average Price Target
The highest estimate is 289.00.
From 5 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow LGND. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.

About

Ligand Pharmaceuticals Incorporated operates as a biopharmaceutical entity, primarily engaged in sourcing and advancing technologies to empower pharmaceutical companies globally in their efforts to discover and develop novel therapeutic solutions. Its diverse portfolio of commercialized products addresses a wide range of medical conditions. For hematologic malignancies, these include Kyprolis and Evomela, both targeting multiple myeloma, as well as Rylaze, a treatment for acute lymphoblastic leukemia and lymphoblastic lymphoma in both adult and pediatric patients. In the realm of infectious diseases, Ligand offers Veklury for moderate to severe COVID-19, Vaxneuvance for preventing invasive Streptococcus pneumoniae disease, and Pneumosil, a pneumococcal conjugate vaccine designed to protect children from pneumonia. Bone health solutions comprise Teriparatide injection for osteoporosis and Duavee for postmenopausal osteoporosis. Other key offerings include Zulresso, a Captisol-enabled formulation of brexanolone for postpartum depression; Nexterone, a Captisol-enabled amiodarone; and Noxafil-IV, a Captisol-enabled posaconazole for intravenous administration. The company’s comprehensive product lineup further extends to the Aziyo portfolio, featuring pericardial repair and CanGaroo envelope extracellular matrix products; Exemptia for autoimmune disorders; Vivitra for breast cancer; Bryxta and Zybev for a variety of indications; and Minnebro for managing hypertension. Beyond its own commercialized products, Ligand Pharmaceuticals collaborates with partners on numerous programs currently undergoing clinical development, targeting conditions such as cancer, seizure disorders, diabetes, cardiovascular ailments, muscle wasting, hepatic and renal diseases, and various other serious illnesses. The company also directly supplies Captisol materials, a proprietary technology frequently integrated into many of its drug formulations. Established in 1987, Ligand Pharmaceuticals is headquartered in Emeryville, California.
Show more...
CEO
Mr. Todd C. Davis Ph.D.
Employees
68
Country
United States
ISIN
US53220K5048

Listings

0 Comments

Share your thoughts

FAQ

What is Ligand Pharmaceuticals stock price today?
The current price of LGND is $263.14 USD — it has increased by +3.09% in the past 24 hours. Watch Ligand Pharmaceuticals stock price performance more closely on the chart.
What is Ligand Pharmaceuticals stock ticker?
Depending on the exchange, the stock ticker may vary. For instance, on exchange Ligand Pharmaceuticals stocks are traded under the ticker LGND.
Is Ligand Pharmaceuticals stock price growing?
LGND stock has risen by +6% compared to the previous week, the month change is a +23.42% rise, over the last year Ligand Pharmaceuticals has showed a +133.82% increase.
What is Ligand Pharmaceuticals market cap?
Today Ligand Pharmaceuticals has the market capitalization of 5.25B
When is the next Ligand Pharmaceuticals earnings date?
Ligand Pharmaceuticals is going to release the next earnings report on August 11, 2026.
What were Ligand Pharmaceuticals earnings last quarter?
LGND earnings for the last quarter are 1.63 USD per share, whereas the estimation was 1.82 USD resulting in a -10.23% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Ligand Pharmaceuticals revenue for the last year?
Ligand Pharmaceuticals revenue for the last year amounts to 536.17M USD.
What is Ligand Pharmaceuticals net income for the last year?
LGND net income for the last year is 248.91M USD.
Does Ligand Pharmaceuticals pay dividends?
Yes, LGND dividends are paid en. The last dividend per share was 0.46 USD. As of today, Dividend Yield (FWD)% is 0%.
How many employees does Ligand Pharmaceuticals have?
As of June 17, 2026, the company has 68 employees.
In which sector is Ligand Pharmaceuticals located?
Ligand Pharmaceuticals operates in the Health & Wellness sector.
When did Ligand Pharmaceuticals complete a stock split?
The last stock split for Ligand Pharmaceuticals was on November 19, 2010 with a ratio of 1:6.
Where is Ligand Pharmaceuticals headquartered?
Ligand Pharmaceuticals is headquartered in Jupiter, United States.